Insmed sees company sales to more than double, expects cash-flow positive without raising capital
Insmed posts Q4 2025 revenue $263.8M (+153% YoY, beat) with non-GAAP EPS -$1.54 (miss) and FY2025 revenue $606.4M; guides BRINSUPRI to ≥$1B 2026 sales and ARIKAYCE $450–$470M,.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.